Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 5
2020 3
2021 5
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
TACkling Cancer by Targeting Selective Protein Degradation.
Noblejas-López MDM, Tébar-García D, López-Rosa R, Alcaraz-Sanabria A, Cristóbal-Cueto P, Pinedo-Serrano A, Rivas-García L, Galán-Moya EM. Noblejas-López MDM, et al. Pharmaceutics. 2023 Oct 10;15(10):2442. doi: 10.3390/pharmaceutics15102442. Pharmaceutics. 2023. PMID: 37896202 Free PMC article. Review.
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.
Noblejas-López MDM, Gandullo-Sánchez L, Galán-Moya EM, López-Rosa R, Tébar-García D, Nieto-Jiménez C, Gómez-Juárez M, Burgos M, Pandiella A, Ocaña A. Noblejas-López MDM, et al. Int J Mol Sci. 2022 May 13;23(10):5476. doi: 10.3390/ijms23105476. Int J Mol Sci. 2022. PMID: 35628286 Free PMC article.
MZ1 co-operates with trastuzumab in HER2 positive breast cancer.
Noblejas-López MDM, Nieto-Jiménez C, Galán-Moya EM, Tebar-García D, Montero JC, Pandiella A, Burgos M, Ocaña A. Noblejas-López MDM, et al. J Exp Clin Cancer Res. 2021 Mar 19;40(1):106. doi: 10.1186/s13046-021-01907-9. J Exp Clin Cancer Res. 2021. PMID: 33741018 Free PMC article.
Poly(Cyclohexene Phthalate) Nanoparticles for Controlled Dasatinib Delivery in Breast Cancer Therapy.
Niza E, Nieto-Jiménez C, Noblejas-López MDM, Bravo I, Castro-Osma JA, Cruz-Martínez F, Buchaca MMS, Posadas I, Canales-Vázquez J, Lara-Sanchez A, Hermida-Merino D, Solano E, Ocaña A, Alonso-Moreno C. Niza E, et al. Among authors: noblejas lopez mdm. Nanomaterials (Basel). 2019 Aug 27;9(9):1208. doi: 10.3390/nano9091208. Nanomaterials (Basel). 2019. PMID: 31461998 Free PMC article.
Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer.
Niza E, Noblejas-López MDM, Bravo I, Nieto-Jiménez C, Castro-Osma JA, Canales-Vázquez J, Lara-Sanchez A, Galán Moya EM, Burgos M, Ocaña A, Alonso-Moreno C. Niza E, et al. Among authors: noblejas lopez mdm. Nanomaterials (Basel). 2019 Dec 16;9(12):1793. doi: 10.3390/nano9121793. Nanomaterials (Basel). 2019. PMID: 31888247 Free PMC article.
Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers.
Juan A, Noblejas-López MDM, Bravo I, Arenas-Moreira M, Blasco-Navarro C, Clemente-Casares P, Lara-Sánchez A, Pandiella A, Alonso-Moreno C, Ocaña A. Juan A, et al. Among authors: noblejas lopez mdm. Cancers (Basel). 2022 Sep 15;14(18):4474. doi: 10.3390/cancers14184474. Cancers (Basel). 2022. PMID: 36139634 Free PMC article.
Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer.
Fuentes-Antrás J, Alcaraz-Sanabria AL, Morafraile EC, Noblejas-López MDM, Galán-Moya EM, Baliu-Pique M, López-Cade I, García-Barberán V, Pérez-Segura P, Manzano A, Pandiella A, Győrffy B, Ocaña A. Fuentes-Antrás J, et al. Among authors: noblejas lopez mdm. Cancers (Basel). 2021 Feb 17;13(4):833. doi: 10.3390/cancers13040833. Cancers (Basel). 2021. PMID: 33671201 Free PMC article.
17 results